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1525-0016/$In primary glioblastomas and other tumor types, the epidermal growth factor receptor (EGFR) is
frequently observed with alterations, such as amplification, structural rearrangements, or over-
expression of the gene, suggesting an important role in glial tumorigenesis and progression. In this
study, we investigated whether posttranscriptional gene silencing by vector-mediated RNAi to
inhibit EGFR expression can reduce the growth of cultured human gli36 glioma cells. To " knock
down" EGFR expression, we have created HSV-1-based amplicons that contain the RNA polymerase
III-dependent H1 promoter to express double-stranded hairpin RNA directed against EGFR at two
different locations (pHSVsiEGFR I and pHSVsiEGFR II). We demonstrate that both pHSVsiEGFR I and
pHSVsiEGFR II mediated knock-down of transiently transfected full-length EGFR or endogenous
EGFR in a dose-dependent manner. The knock-down of EGFR resulted in the growth inhibition of
human glioblastoma (gli36-luc) cells both in culture and in athymic mice in vivo. Cell cycle analysis
and annexin V staining revealed that siRNA-mediated suppression of EGFR induced apoptosis.
Overall HSV-1 amplicons can mediate efficient and specific posttranscriptional gene silencing.R
Th
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Glioblastoma multiforme (GBM) is the most common
and most aggressive brain tumor. With an incidence of 3–
4/100,000, GBM constitutes approximately 20–25% of all
primary intracranial neoplasms [1,2]. Overall effective-
ness of standard treatment (surgery, radiation, chemo-
therapy) is limited as these tumors invariably recur. The
mean life expectancy is only 1–2 years after diagnosis [3].
Together with all brain tumors, GBM constitutes the
second most common cause of death from a neurological
disorder after stroke [3,4].
A complex series of molecular changes occurs in the
development of GBM including loss, mutation, or
hypermethylation of tumor suppressor and cell cycle-
regulating genes (e.g. TP53, CDKN2A/p16, p14ARF,
PTEN), as well as activation or amplification of onco-
genes and growth factors and/or their receptors (e.g.,
MDM2, CDK4, cyclins D1 and D3, EGFR, PDGFR, andTHERAPY Vol. 12, No. 5, November 2005
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.00TGF-h) [5,6]. During progression from low-grade astro-
cytoma (WHO grade II) to anaplastic astrocytoma (WHO
grade III) and to GBM (WHO grade IV), a step-wise
accumulation of genetic alterations may occur [7]. These
so-called secondary glioblastomas can be distinguished
from primary de novo glioblastomas on the basis of
molecular genetic findings. In primary GBM, overex-
pression or amplification of the epidermal growth factor
receptor (EGFR) plays a central role in glial tumori-
genesis and is found in up to 50% of all cases. These
EGFR alterations have also been described in a number
of further premalignant and malignant diseases such as
mammary and hepatic carcinoma [8].
EGFR is a transmembrane glycoprotein of 170 kDa
and is composed of an extracellular ligand-binding
domain, a single hydrophobic membrane-spanning
domain, and a cytoplasmic tyrosine kinase domain [9].
In the EGFR-Ras signaling pathway, the binding of803
FIG. 1. Schematic drawing of the pHSVsi amplicon vector. (A) Sequences
encoding siRNA with 19 nt of homology (N19) to the target sequences are
synthesized as 64-bp double-stranded DNA oligonucleotides and inserted
downstream of the H1 RNA promoter. The amplicon contains two HSV-1
elements, an origin of DNA replication (oriS) and a DNA packaging/cleavage
signal (pac), and EGFP coding sequences under the control of the HSV-1 IE 4/5
promoter. (B) The siRNA target sequences within EGFP and exons 1 and 3 of
EGFR (I and II) are shown.
ARTICLE doi:10.1016/j.ymthe.2005.07.534ligands to EGFR activates Ras, which in turn activates
Raf. The activated Raf kinase can initiate the mitogen-
activated protein (MAP) kinase cascade. The activated
MAP kinase then migrates into the nucleus and induces
phosphorylation of transcription factors (e.g., c-myc, c-
jun, and c-ets), which affects gene expression and
ultimately cell growth [9].
Several studies have exploited EGFR as a target for
cancer-therapeutic procedures, including the use of (i)
anti-EGFR antibodies [10–12], (ii) toxin-conjugated
ligands [13], and (iii) tyrosine kinase-specific inhibitors
[14]. A promising, new approach is the selective degra-
dation of mRNA by RNA interference (RNAi). RNAi is a
sequence-specific, posttranscriptional gene silencing
mechanism, which is triggered by small interfering,
double-stranded RNA (siRNA) and causes degradation of
mRNA homologous in sequence to the siRNA. Here, we
used helper-virus-free HSV-1 amplicon vectors [15]
expressing siRNAs to (i) mediate posttranscriptional
silencing of EGFR and (ii) analyze the effect of EGFR
suppression on the proliferation of human glioblastoma
cells in culture and in vivo.
RESULTS
HSV-1 Amplicon-Encoded siRNAs Inhibit the
Synthesis of EGFR and EGFP
To bknock downQ EGFR expression, we have created HSV-
1 amplicon vectors that contain the HSV-1 immediate-
early 4/5 promoter to express enhanced green fluorescent
protein (EGFP) and the RNA polymerase III dependent H1
promoter to express double-stranded hairpin RNA direc-
ted against either EGFR at two different locations
(pHSVsiEGFR I and pHSVsiEGFR II) or EGFP (Fig. 1). To
test the functionality of these vectors, we infected Vero 2-
2 cells and human glioma gli36-luc cells at a multiplicity
of infection (m.o.i.) of 10 transducing units (TU) per cell
(Fig. 2A). In gli36-luc cells, pHSVsiEGFP mediated the
complete inhibition of EGFP expression by day 1 after
infection; in Vero 2-2 cells, inhibition of EGFP was
initially inefficient, but almost complete after 7 days.
EGFP fluorescence in the pHSVsiEGFR I- and II-infected
cultures was present in virtually 100% of the cells and was
stable over at least 7 days.
To test the functionality of the EGFR-specific siRNAs,
we first transfected Vero 2-2 cells with a vesicular
stomatitis virus G protein (VSVG)-tagged EGFR expres-
sion vector (pMVEGFR-VSV) and, 4 h later, mock infected
or infected them with pHSVsiEGFP or pHSVsiEGFR I or II
amplicons. Four days later, we fixed the cells and stained
them with an anti VSVG antibody and a Cy3-conjugated
secondary antibody. We examined the cells under the
fluorescence microscope using a rhodamine filter, which
allows codetection of both EGFR-VSVG (red, transfected
cells) and EGFP (green, amplicon-transduced cells). The
results are shown in Fig. 2B and can be summarized as804follows: Transfection of the cells with pMVEGFR-VSV
resulted in approximately 10% EGFR-VSVG-positive cells.
Superinfection of these cultures with pHSVsiEGFR I or
pHSVsiEGFR II reduced the number of EGFR-VSVG-
positive cells by about 40%. By increasing the m.o.i.
from 1 to 5 TU of pHSVsiEGFR II per cell, the number of
green (vector transduced) cells increased threefold, while
the number of EGFR-VSVG-positive cells (red) was further
reduced by 60–70%. Very few cells were positive for both
EGFP- and EGFR-VSVG in the pHSVsiEGFR I- and II-
infected cultures, indicating that, once a cell is trans-
duced by amplicon, suppression of EGFR-VSVG synthesis
was efficient. By contrast, infection of the cells with the
control amplicon (pHSVsiEGFP, m.o.i. of 5) did not
reduce the number of EGFR-VSVG-positive cells, com-
pared to mock-infected cells. Moreover, although the
number of EGFP-fluorescent cells was small (due to
posttranscriptional silencing of EGFP), EGFR-VSVG and
EGFP were codetected in a high proportion of the cells,MOLECULAR THERAPY Vol. 12, No. 5, November 2005
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FIG. 2. HSV-1 amplicon-mediated posttran-
scriptional silencing of EGFR and EGFP. (A)
Vero 2-2 cells or gli36-luc cells were infected
with pHSVsiEGFR I, pHSVsiEGFR II, or
pHSVsiEGFP amplicon vectors at an m.o.i.
of 5. EGFP, which is expressed from all three
vectors, was monitored at the indicated days
postinfection (pi) and magnification (10,
40) under the fluorescence microscope. (B)
2-2 cells were first transfected with the EGFR-
VSVG expression plasmid (pMVEGFR-VSV)
and, 4 h later, mock infected or infected
with pHSVsiEGFR I, pHSVsiEGFR II, or
pHSVsiEGFP at the indicated m.o.i. Four days
after infection, cells were fixed and stained
with an anti-VSVG antibody and examined
under the fluorescence microscope using a
red filter (rhodamine), which allows code-
tection of both EGFR-VSVG (red) and EGFP
(green). Arrows show cells that are positive
for both colors.
ARTICLEdoi:10.1016/j.ymthe.2005.07.534indicating that transduction of the cells with the control
amplicon did not affect EGFR-VSVG expression. These
results demonstrate the efficiency and specificity of the
vector-encoded siRNAs for their respective targets, EGFR
and EGFP.
HSV-1 Amplicon-Mediated EGFR-Specific siRNA
Expression Reduces the Levels of Endogenous EGFR
Transcript in gli36-luc Cells
We evaluated the effects of HSV-1 amplicon-mediated
siRNA synthesis on the expression of EGFR by reverse
transcription and PCR (RT-PCR) analysis. We mock
infected Gli36-luc cells or infected them with
pHSVsiEGFR I, pHSVsiEGFR II, or pHSVsiEGFP (m.o.i.
of 5). We harvested the cells and isolated total RNA at 4
days after infection. RT-PCR revealed that the EGFR
transcripts were significantly reduced in both
pHSVsiEGFR I- and II-infected cells (Fig. 3A, lanes 3
and 4), but not in control amplicon- (Fig. 3A, lane 2) or
mock- (lane 1) infected cells. The level of the endoge-
nous human glyceraldehyde-3-phosphate dehydrogen-MOLECULAR THERAPY Vol. 12, No. 5, November 2005
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Quantification of the RT-PCR products obtained from
the gli36-luc cells revealed a reduction of 50–75% in
EGFR mRNA levels following infection with pHSVsiEGFR
I or pHSVsiEGFR II, compared to mock-infected or
pHSVsiEGFP-infected cells (Fig. 3B). We confirmed the
functionality and specificity of the vector-encoded siR-
NAs also by Western analysis. While endogenous EGFR
protein was almost undetectable in pHSVsiEGFR I- or
pHSVsiEGFR II-infected gli36-luc cells, it was readily
detected in mock-infected or pHSVsiEGFP-infected cells
(Fig. 3C). As a control, the levels of endogenous h-tubulin
were not affected by any of the vectors tested (Fig. 3C).
Vector-Mediated siRNA Targeting EGFR Inhibits
Growth of Human Glioma Cells in Culture and in Vivo
We determined different proliferation parameters to assess
the growth capability of gli36-luc cells in culture and,
following subcutaneous implantation, in nude mice. For
all assays, gli36-luc cells were either mock infected or
infected with HSV-1 amplicons at an m.o.i. of 5. As a first805
FIG. 3. HSV-1 amplicon-mediated EGFR-specific siRNA expression reduces the
levels of endogenous EGFR in gli36-luc cells. (A) Gli36-luc cells were mock
infected or infected with HSV-1 amplicons expressing EGFP-, EGFR I-, or EGFR
II-specific siRNAs (m.o.i. of 5). Four days later, total RNA was isolated and
reverse transcribed, and conventional PCR was performed. A representative
agarose gel from three independent RT-PCRs is shown. Lane 1, mock; lane 2,
pHSVsiEGFP; lane 3, pHSVsiEGFR I; lane 4, pHSVsiEGFR II; lane 5, H2O; lane 6,
pMVEGFR-VSV plasmid DNA; lane M, 1 kb molecular weight marker. The
arrows indicate EGFR- and GAPDH-specific RT-PCR products. (B) After
scanning and analyzing the RT-PCR product bands by using Image Quant
5.2 (Molecular Dynamics, Sunnyvale, CA, USA), we calculated relative mRNA
levels of EGFR by normalization with GAPDH mRNA levels. The results were
obtained from three independent experiments. *Significant reduction (P b
0.05). (C) Gli36-luc cells were infected as in (A), and proteins were resolved by
SDS–polyacrylamide gel electrophoresis and analyzed using monoclonal
antibodies that recognize EGFR or h-tubulin.
FIG. 4. Effects of posttranscriptional silencing of EGFR on cellular proliferation
of human glioblastoma cells in culture. Cells were infected as described unde
Materials and Methods and proliferation was assayed by (A) cell number and
(B) BrdU incorporation. All values are presented as the mean F SD of three
independent experiments. *Significant reduction (P b 0.05).
ARTICLE doi:10.1016/j.ymthe.2005.07.534parameter, we determined the cell number at days 5 and 10
after infection. There was a significant difference in the
growth rate between pHSVsiEGFR I- or II- and control
amplicon- or mock-infected cells, with a 40–50% reduc-
tion in growth following expression of the EGFR-specific
siRNAs (Fig. 4A). Infection with pHSVsiEGFR I or II, but
not with control amplicon, also significantly reduced the
growth of a different human glioma cell line (U87; not
shown). Because the gli36-luc cells constitutively express
the firefly luciferase gene, we determined luciferase
activity as a second proliferation parameter. We observed
a pronounced reduction of luciferase activity in cells
infected with pHSVsiEGFR I and II (not shown). We used806a BrdU incorporation ELISA as a third parameter for cell
proliferation. BrdU is a thymidine analogue that is
incorporated into replicating DNA and can be quantified
using antibodies [16]. We found that pHSVsiEGFR I or II,
but not pHSVsiEGFP, significantly decreased BrdU incor-
poration in gli36-luc cells, compared to mock-infected
cells (Fig. 4B). We performed soft agarose assays to test
whether targeting of EGFR by siRNA can reduce the ability
of gli36-luc cells to form colonies. At 24 h after infection,
we placed the cells into medium containing soft agarose
and evaluated colony formation after 11 days. Cells
infected with pHSVsiEGFR I and II formed fewer (40–
50%) and smaller colonies than mock-infected cells or
cells infected with the control amplicon (Figs. 5A and 5B).
We performed two experiments to investigate whether the
observed reduction in the growth capability of the gliomaMOLECULAR THERAPY Vol. 12, No. 5, November 2005
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FIG. 5. The effects of EGFR inhibition on tumor growth of gli36-luc cells in vitro and in vivo. (A) Colony soft agar assay was evaluated as an in vitro tumor growth
assay. The colony numbers in mock-infected plates were taken as a value of 100% colony formation. (B and C) Representative colonies were photographed at 11
days after infection using a light microscope or a fluorescence microscope equipped with a filter specific for EGFP. Original magnification: (B) 2.5, (C) 40. The
values in (A) are presented as the mean F SD of three independent experiments. *Significant reduction (P b 0.05). (D) To assess the growth capacity in vivo,
gli36-luc cells were infected and, 24 h later, infused sc into athymic mice (1  106 cells per animal; n = 4). Luciferase expression was visualized 2 weeks later using
the Xenogen IVIS system. The numbers indicate photons per 10 s.
ARTICLEdoi:10.1016/j.ymthe.2005.07.534cells resulted from inhibition of the cell cycle and/or the
induction of apoptosis. We mock infected Gli36-luc cells
or infected them with HSV-1 amplicons, eitherMOLECULAR THERAPY Vol. 12, No. 5, November 2005
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later, analyzed them for cell cycle distribution and
apoptosis. FACS analyses showed that approximatelyFIG. 6. Cell cycle analysis and apoptosis. Gli36-luc cells
were mock infected or infected with HSV-1 amplicons
expressing EGFP- or EGFR II-specific siRNAs (m.o.i. of
5). After 4 days, the cells were stained with (A and B)
propidium iodide or (C) annexin V-Cy3.
807
FIG. 7. Effects of HSV-1 amplicon-mediated siRNA expression on the growth of preestablished tumors in athymic mice. Gli36-luc cells were subcutaneously
injected into the right flanks of athymic mice (nu/nu, 5-week-old males). (A) Two weeks after implantation, tumors were monitored by IVIS and the animals were
divided into groups of four. The number and photon counts of each animal (top), as well as the average photon counts of the group (bottom), are shown. Vectors
(1  106 TU in 20 Al) were injected into tumors three times per week for 2 weeks. Then, the tumors were removed (B and C) to determine the volumes and (D) for
immunohistochemical detection of EGFR. The arrows in (D) point to EGFR-positive cells (brown cytoplasmic staining). *Significant reduction (P b 0.05).
ARTICLE doi:10.1016/j.ymthe.2005.07.534
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ARTICLEdoi:10.1016/j.ymthe.2005.07.53456% of the pHSVsiEGFR II-infected cells were in the sub-
G1 fraction (representing apoptotic cells). In mock-
infected cultures or cultures infected with the control
vector pHSVsiEGFP the amounts of cells in the sub-G1
fraction were 9.5 and 16%, respectively (Figs. 6A and
6B). We obtained similar results with U87 cells (sub-
G1 fractions: mock, 19.4%; siEGFP, 26.7%; siEGFRII,
57.5%). We performed annexin staining to confirm
that siRNA-mediated inhibition of EGFR can induce
apoptosis. We found a population of 40% apoptotic
cells in the presence of EGFR gene silencing. We
observed no relevant apoptosis in mock-infected cells
or in cells infected with the control amplicon
pHSVsiEGFP (Fig. 6C).
Next we tested the growth capacity of gli36-luc cells
following implantation in mice. For this we chose
pHSVsiEGFR II, as this vector was consistently more
efficient in all in vitro assays. We infected the cells as
above and, 24 h later, trypsinized, washed, and subcuta-
neously infused them into nude mice (106 cells per
animal). We placed one portion of the cells (105) back
into the tissue culture dish and further cultivated them;
these cells were viable and the pHSVsiEGFR II-infected
cells continued to express EGFP for at least 7 days (data
not shown). Bioluminescence imaging performed 14
days after implantation showed that all animals infused
with mock-infected gli36-luc cells and three of four
animals infused with control amplicon pHSVsiEGFP-
infected cells emitted light from the infusion site.
However, none of the animals infused with pHSVsiEGFR
II-infected gli36-luc cells showed light emission mark-
edly above background level at this time point (Fig. 5C);
luciferase activity (5704 photons per 10 s) was detectable
in one of these animals for the first time at 3 weeks after
infusion. We also examined the effects of HSV-1
amplicon-mediated inhibition of EGFR on the growth
of preestablished tumors. For this experiment, we
infused 3.5  106 gli36-luc cells subcutaneously into
nude mice. Two weeks after implantation, we scored
tumors by IVIS and divided the animals into three
groups with comparable photon counts (Fig. 7A). Then,
we injected the tumors three times per week with vector
(pHSVsiEGFP or pHSVsiEGFR II; 1  106 TU in 20 Al
phosphate-buffered saline (PBS)) or PBS (20 Al). After 2
weeks of treatment, the pHSVsiEGFR II-treated tumors
were significantly smaller and expressed markedly lower
EGFR levels than grafts treated with pHSVEGFP or PBS
(Figs. 7B–7D).
DISCUSSION
The genetic abnormalities of EGFR in glioblastomas have
led to extensive studies of its relationship to cell
proliferation, differentiation, and patient survival as well
as its potential as a target of a number of alternative
therapeutic interventions [17,18]. One therapeutic inter-MOLECULAR THERAPY Vol. 12, No. 5, November 2005
Copyright C The American Society of Gene Therapyvention, the specific downregulation of EGFR by virus
vector-mediated delivery of siRNAs to inhibit glioma cell
proliferation, has not yet been assessed. HSV-1-based
vectors are well suited to treat diseases affecting the
central nervous system, including the selective killing of
brain tumor cells with replication-conditional HSV-1
vectors, an approach that has moved already toward
clinical application [19,20]. In addition to replication-
conditional HSV-1 mutants, the bgutlessQ HSV-1 ampli-
con vector has several properties that make it a promising
candidate gene transfer vehicle. HSV-1 amplicons are
bacterial plasmids that contain two noncoding genetic
elements from HSV-1, an origin of DNA replication and a
DNA packaging/cleavage signal, which allow their repli-
cation and packaging as a concatemer of 150 kb into
HSV-1 particles. Depending on the size of the seed
amplicon, numerous copies of the transgene sequences
are packaged in one vector particle (e.g., approx 22 copies
in a pHSVsiEGFR vector particle), supporting high
expression levels. As no virus proteins are encoded,
amplicons are nearly nontoxic when packaged without
contaminating helper virus. Moreover, amplicon vectors
can infect most mammalian cell types, including human
glioma cells [21–26].
This study establishes the basis for the viral vector-
mediated, posttranscriptional suppression of epidermal
growth factor receptor as a potential therapeutic inter-
vention in neuro-oncology. Using helper-virus-free HSV-
1 amplicon vectors to express siRNAs, we achieved a
significant and specific inhibition of either transfected
or endogenous EGFR expression in Vero 2-2 cells or
human gli36-luc cells, respectively (Figs. 2 and 3);
GAPDH and h-tubulin expression was not affected (Fig.
3). The pHSVsiEGFP amplicon vector, which expresses
EGFP from the HSV-1 immediate-early 4/5 promoter and
EGFP-specific siRNA from the H1 promoter mediated the
efficient posttranscriptional silencing of EGFP, but not
that of EGFR or GAPDH, further demonstrating the
specificity of the assay (Figs. 2A and 3). The down-
regulation of EGFR had a significant effect on the
growth capability of the glioma cells both in culture
and in vivo, which was expected, as the transfection of
EGFR-specific, synthetic siRNAs into cultured glioblas-
toma cell lines was recently reported to induce a
blockade at the G2M phase of the cell cycle followed
by apoptosis [27]. An antiproliferative effect following
transfection of EGFR-specific siRNAs was observed in
other cultured tumor cells as well [28,29]. In this study
we show that the reduced cell proliferation following
vector-delivered siRNA inhibition of EGFR was due to
apoptosis (Fig. 6).
The advantage of the HSV-1 amplicon approach
presented in our study is that it is safe, because the
vector contains no viral genes and remains episomally
in the cell nucleus, and can target cells and tissues not
accessible by transfection. Moreover, the large transgene809
ARTICLE doi:10.1016/j.ymthe.2005.07.534capacity of HSV-1 amplicons allows the inclusion of
additional genes that have therapeutic, regulatory, and/
or imaging functions. The incorporation of the EGFP
marker gene in our vectors allowed the titration of the
vector stocks and the visualization of cell transduction
over time. For example, in the cell proliferation assays,
we noted that a large fraction of the cells was still EGFP
positive at 11 days after infection with pHSVsiEGFR I or
II vectors, while no EGFP-positive cells were observed at
11 days after infection with the pHSVsiEGFP vector,
indicating that RNA interference was still effective at
this time point.
In conclusion, the approach presented here provides a
novel tool to study the function of EGFR in tumor
development and may find applications in gene therapy
for gliomas. HSV-1 amplicons are easy to construct and,
therefore, allow the rapid evaluation of numerous siRNA
target sequences, tailored to the physical state of the
EGFR gene or other target genes in a specific tumor. It will
be interesting to test the effect of vector delivery into
preestablished tumors, perhaps in combination with
replication-conditional HSV-1 helper viruses to increase
the intratumoral spread of the vectors. Finally, the
strategy described here is not limited to neuro-oncolog-
ical conditions, but may be applicable to neurodegener-
ative disorders as well, such as the recently reported




Human glioma cells (gli36) were kindly provided by Dr. David N. Louis
(Harvard Medical School, Massachusetts General Hospital, Charlestown,
MA, USA). These cells are negative for both GFAP and S-100 on
immunohistochemistry and they carry a p16-CDKN2A homozygous
deletion; moreover, gli36 cells do not have the EGFR gene amplification
or the deletion of exons 2–7 (DEGFR), as these genetic abnormalities are
not stably maintained in most cultured glioma cells (D.N. Louis, personal
communication). To generate glioma cells stably expressing luciferase
(gli36-luc), gli36 cells were cotransfected with plasmids pSV2Neo and
pGL3, which expresses firefly luciferase from the SV40 early promoter
(Promega, Wallisellen, Switzerland). Gli36-luc-positive clones were
selected using 2000 Ag/ml G418 in DulbeccoTs minimal essential medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and checked
for luciferase expression by a luminometer. The clone with the highest
luciferase level was used for further studies. The selected gli36-luc cell
clone and Vero 2-2 cells [31] were grown in DMEM supplemented with
10% FBS, 500 Ag/ml G418, 100 units/ml penicillin, and 100 Ag/ml
streptomycin at 378C in a 5% CO2/95% O2 atmosphere.
Plasmids
pMVEGFR-VSV (kindly provided by Dr. Mark I. Greene, University of
Pennsylvania School of Medicine, Philadelphia, PA, USA) expresses a full-
length EGFR protein fused to VSVG under the control of the CMV
immediate-early (IE) 1 promoter/enhancer [32]. Plasmid pSUPER, which
contains the RNA polymerase III-dependent H1 promoter and a well-
defined start of transcription and a termination signal consisting of four
consecutive thymidines, was described previously [33]. To create the basic
pHSVsi amplicon, the 3.6-kb BamHI/SalI fragment of ploxP-A-H6 (kindly
provided by Dr. Yoshinaga Saeki, Ohio State University Medical Center,
Columbus, OH, USA), which contains an HSV-1 origin of DNA replication810(OriS), the HSV-1 DNA packaging/cleavage signal (Pac), and an EGFP
under control of the HSV-1 IE 4/5 promoter, was first inserted between the
BamHI/SalI sites of pUC19. The resulting plasmid was designated pUC19-
OriS-Pac-EGFP. The BamHI/PstI fragment of pUC19-OriS-Pac-EGFP was
then inserted between the BamHI and the PstI sites of pSUPER. The
resulting amplicon, pHSVsi, expresses EGFP to facilitate titration (Fig. 1A).
DNA oligonucleotides targeting EGFR at two different locations (Fig. 1)
were synthesized (Microsynth, Balgach, Switzerland) as 64-mer sense and
antisense oligonucleotide templates (19  2 nucleotides specific to the
targeted genes and 26 nucleotides for restriction enzyme recognition sites
and hairpin structure) and inserted into pHSVsi between the BglII and the
HindIII sites. An amplicon that contains DNA oligonucleotides targeting
EGFP (Fig. 1) was used as a control. These amplicons are designated here
as pHSVsiEGFR I, pHSVsiEGFR II, and pHSVsiEGFP. Amplicon packaging
was performed as described [23] and titered (TU/ml) by counting the
number of green cells 24 h following infection of Vero 2-2 cells using a
fluorescence microscope.
Western Analysis
Gli36-luc cells were seeded into 6-cm-diameter tissue culture plates
(1.2  106 cells per plate) and, the following day, either mock infected
or infected with HSV-1 amplicon vectors (m.o.i. of 5). After 4 days, cells
were harvested, and total protein was separated on a SDS–12%
polyacrylamide gel and blotted onto nitrocellulose. The membrane
was blocked with 5% nonfat dry milk in PBS-T (PBS containing 0.05%
Tween 20) for 2 h at 378C and then rinsed once with PBS-T and washed
twice for 15 min and twice for 5 min at room temperature with TBS-T
(50 mM Tris–HCl, pH 7.9, 150 mM NaCl, 0.01% Tween 20). The primary
antibodies were diluted 1:50 (anti-EGFR antibody; NeoMarkers, Fremont,
CA, USA) or 1:1000 (anti-h-tubulin antibody; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA) in TBS-T containing 2% nonfat dry milk and
applied to the membrane. After incubation overnight at 48C, the
membrane was washed twice for 15 min and twice for 5 min at room
temperature with TBS-T and then incubated for 1 h at room temperature
with a horseradish-conjugated rabbit anti-mouse secondary antibody
(Santa Cruz Biotechnology) diluted 1:2500 in TBS-T containing 2%
nonfat dry milk. Bands were visualized using the ECL system according
to instructions provided by the supplier (Amersham, Buckinghamshire,
UK).
RT-PCR Analysis
Total RNA from 1  105 gli36-luc cells either infected with amplicons
(m.o.i. of 5) or mock infected was isolated using the Micro-to-Midi total
RNA isolation kit (Invitrogen, Basel, Switzerland). Total RNA was reverse
transcribed with random primers using the RT-PCR kit from Promega.
PCR for EGFR was performed by using the following primers: forward
primer, 5V-CACCTGCGTGAAGAAGTGTCC-3V; reverse primer, 5V-
CCGTCCTGTGCAGGTGATGTT-3V. PCR amplification of the housekeep-
ing gene GAPDH was performed as control of sample loading and to allow
normalization between samples. The following primers were used for the
GAPDH PCR: forward primer, 5V-GGGGAGCCAAAAGGGTCATCATCT-3V;
reverse primer, 5V-ACGCCTGCTTCACCACCTTCTTGA-3V. PCR was per-
formed under the following conditions: EGFR, 958C for 2 min; 35 cycles at
948C for 1 min, 60.58C for 1 min, 728C for 2 min; and a final extension at
728C for 10 min; GAPDH, 958C for 2 min; 35 cycles at 948C for 1 min,
638C for 1 min, 728C for 2 min; and a final extension at 728C for 10 min.
Indirect Immunofluorescence
Vero 2-2 cells were seeded in 24-well plates at 5  104 cells/well and, the
following day, transfected with pMVEGFR-VSV (0.2 Ag/well) using Lip-
ofectamine 2000 (Invitrogen). After 4 days of incubation, the cells were
fixed with 4% paraformaldehyde in PBS for 20 min at room temperature.
After incubation in 0.1 M glycine (in PBS) for 15 min, the cells were
permeabilized with 0.2% Triton X-100 in PBS for 15 min and then
incubated for 1 h at room temperature with monoclonal mouse anti-
VSVG antibody (Sigma; 1:5000 in 3% BSA, 0.2% Triton X-100 in PBS). As a
fluorescent secondary antibody, rabbit anti-mouse IgG–Cy3 was used
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Cells
were examined under a Zeiss Axiovert 100 fluorescence microscope
equipped with a Hamamatsu CCD digital camera and a filter specific forMOLECULAR THERAPY Vol. 12, No. 5, November 2005
Copyright C The American Society of Gene Therapy
ARTICLEdoi:10.1016/j.ymthe.2005.07.534rhodamine, which allows covisualization of both Cy3 (EGFR-VSVG) and
EGFP.
Cellular Proliferation Assays
Growth rate. Gli36-luc cells (5  103) were seeded in each well of a six-
well plate and infected on the next day with HSV-1 amplicons (m.o.i. of
5). Cells were counted at 5 and 10 days after infection using a
hemocytometer.
Luciferase activity. Cells were infected with HSV-1 amplicons as
described above and, 5 or 10 days later, lysed by three cycles of freezing
and thawing. After centrifugation (14,000 rpm, 5 min), 10 Al of super-
natant was mixed with 100 Al of luciferase assay solution (Promega) and
analyzed in a luminometer.
BrdU index. Gli36-luc cells (1  103) were infected with HSV-1 amplicons
(m.o.i. of 5). Cells were fixed at 5 days after infection and DNA was
denatured using reagents supplied with the cell proliferation assay kit
(Roche Diagnostics, Indianapolis, IN, USA). Cells were incubated with
anti-BrdU peroxidase conjugate, washed, and incubated with color
development substrate. The absorbance of the samples was measured at
450-nm wavelength (A450).
Statistical analysis. All measurements for cell proliferation were per-
formed in triplicate and the values are expressed as means F SD; P values
were calculated by using the Student t test, and values of P b 0.05 were
regarded as significant.
Colony Soft Agarose Assay
Colony soft agarose assays were performed as described in detail elsewhere
[34]. Briefly, each well of a six-well plate was coated with 2 ml of bottom
agarose mixture (DMEM/10% FBS/0.6% agarose). After the bottom layer
had solidified, 2 ml of top agarose mixture (DMEM/10% FBS/0.4%
agarose) containing 5  103 cells, infected at an m.o.i. of 5 TU per cell
with either pHSVsiEGFP or pHSVsiEGFR I or II amplicons, was added to
each well. Triplicate cultures were incubated in 5% CO2/95% O2
atmosphere at 378C. Colonies were counted and photographed 11 days
after the cells were plated. The number of colonies formed in the mock-
infected cultures was set as the value of 100% colony formation.
FACS Analysis and Apoptosis Assays
Gli36-luc cells were seeded into 12-well plates (1  105 cells per well) and,
on the next day, mock infected or infected with HSV-1 amplicon vectors
(m.o.i. of 5). After 4 days, the cells were fixed with 70% ethanol on ice for
30 min, washed with PBS, treated with RNase A (100 Ag/ml) at 378C for 30
min, and then, 20 Ag/ml propidium iodide (Sigma Chemical Co., St.
Louis, MO, USA) was added. A total of 64,000 stained nuclei were
analyzed in a FACSCalibur flow cytometer (Becton–Dickinson, Basel,
Switzerland) using the BD-CellQuest software (Becton–Dickinson). DNA
histograms were analyzed using WinMDI 2.8 software (Purdue University
Cytometry Laboratories, West Lafayette, IN, USA). Apoptotic cell death
was determined using the Annexin V–Cy3 Apoptosis Detection Kit
(Abcam, Cambridge, UK) according to the manufacturerTs instruction.
Briefly, infection was performed as above, and cells were harvested at 4
days after infection, washed with PBS, and then suspended in annexin V
binding buffer. The cells were stained for 15 min at room temperature in
the dark and analyzed on a FACSAria flow cytometer using BD-FACSDiVa
software (Becton–Dickinson).
Glioma Cell Implantation and Bioluminescence Imaging
All animal procedures were approved and performed according to
guidelines issued by the Committee of Animal Care of the Canton of
Zurich. Human glioblastoma gli36-luc cells were either mock infected or
infected with pHSVsiEGFR II or pHSVsiEGFP at an m.o.i. of 5 TU per cell.
After 24 h, the cells were trypsinized, washed, and subcutaneously
implanted (1  106 cells in 100 Al per animal) into the flanks of athymic
mice (nu/nu, 5-week-old males, four animals per group; Charles River
Laboratories, Germany). After 14 days, the animals were first injected
intraperitoneally with d-luciferin (150 Ag/g body wt; Xenogen) and then
anesthetized with isoflurane. Ten minutes after the injection of d-MOLECULAR THERAPY Vol. 12, No. 5, November 2005
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and quantified by Living Image analysis software (Xenogen). A surface
image of the animals was acquired, onto which the pseudocolor image
representing the distribution of the photon counts was projected to allow
correlation of bioluminescence and anatomy. For the treatment of
preestablished tumors, 3.5  106 gli36-luc cells in 100 Al PBS were
subcutaneously injected into the right flanks of athymic mice (nu/nu, 5-
week-old males). Two weeks after implantation, tumors were monitored
by IVIS as described above, and the animals were divided into groups of
four. Vectors (1  106 TU in 20 Al) were injected into tumors three times
per week for 2 weeks. Then, the tumors were removed and photo-
graphed, and the tumor volumes were determined using AxionVision
2.05 software (Zeiss, Feldback, Switzerland). For immunohistochemical
detection of EGFR, tumor sections were incubated overnight at room
temperature with a goat anti-EGFR antibody (1:15; Santa Cruz Biotech-
nology). LSAB+ (DAKO Cytomation, Zug, Switzerland) was used as the
secondary antibody and aminoethylcarbazole (Zymed, San Francisco, CA,
USA) as the chromagen according to instructions provided by the
manufacturers.
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